<DOC>
	<DOC>NCT01774825</DOC>
	<brief_summary>After 2 weeks of run-in period, subjects are randomized to either IQP-CL-101 or a matching placebo. Over 8 weeks, the subjects are monitored for improvements in IBS symptoms</brief_summary>
	<brief_title>IQP-CL-101 in IBS Management</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Fulfils RomeIII criteria for IBS diagnosis Females' agreement to use appropriate birth control methods during the active study period for females of childbearing potential Subject declares in writing his/her consent to participate, understands requirements of the study and is willing to comply Known sensitivity to any of the ingredients of IQPCL101 Clinically relevant abnormalities in colonoscopy within the last 2 years prior to randomization Other causes of IBS symptoms such as inflammatory bowel disease (IBD), microscopic colitis, celiac disease, history of abdominal obstruction, cholecystitis, pancreatitis, ileus, or any gastrointestinal bleeding Use of medications that could influence GI functions (e.g. antibiotics, laxatives, opioids, glucocorticoids, anticholinergics, or antidiarrheals) within 1 month prior to randomization Clinically relevant excursions of safety parameters Any other conditions deemed relevant by the investigator(s)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>IBS</keyword>
</DOC>